Literature DB >> 9162520

Why do so many cancer patients fail to respond to interferon therapy?

S Einhorn1, D Grander.   

Abstract

Since their first use in the clinic some 25 years ago, interferons (IFNs) have become accepted therapy in a range of cancer forms. However, although in some patients they induce remission, in the great majority they are of no benefit or, at best, lead only to minor improvements. This review considers possible reasons for these failures.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9162520     DOI： 10.1089/jir.1996.16.275

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN： 1079-9907            Impact factor:   2.607


  19 in total

1.  IFNalpha/beta promotes cell survival by activating NF-kappa B.

Authors:  C H Yang; A Murti; S R Pfeffer; L Basu; J G Kim; L M Pfeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Interferon alpha activates NF-kappaB in JAK1-deficient cells through a TYK2-dependent pathway.

Authors:  Chuan He Yang; Aruna Murti; William J Valentine; Ziyun Du; Lawrence M Pfeffer
Journal:  J Biol Chem       Date:  2005-05-09       Impact factor: 5.157

Review 3.  Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer.

Authors:  Qi Bao; Yue Zhao; Hanno Niess; Claudius Conrad; Bettina Schwarz; Karl-Walter Jauch; Ralf Huss; Peter J Nelson; Christiane J Bruns
Journal:  Stem Cells Dev       Date:  2012-06-26       Impact factor: 3.272

4.  Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer.

Authors:  Jennifer L Dembinski; Shanna M Wilson; Erika L Spaeth; Matus Studeny; Claudia Zompetta; Ismael Samudio; Katherine Roby; Michael Andreeff; Frank C Marini
Journal:  Cytotherapy       Date:  2013-01       Impact factor: 5.414

5.  Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival.

Authors:  Chuan He Yang; Aruna Murti; Lawrence M Pfeffer
Journal:  J Biol Chem       Date:  2005-07-11       Impact factor: 5.157

6.  Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha.

Authors:  S Ozawa; H Shinohara; H O Kanayama ; C J Bruns; C D Bucana; L M Ellis; D W Davis; I J Fidler
Journal:  Neoplasia       Date:  2001 Mar-Apr       Impact factor: 5.715

7.  Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice.

Authors:  X Q Qin; N Tao; A Dergay; P Moy; S Fawell; A Davis; J M Wilson; J Barsoum
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

8.  ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway.

Authors:  Young Joo Jeon; Joon Seok Choi; Jung Yun Lee; Kyung Ryun Yu; Sangman Michael Kim; Seung Hyeun Ka; Kyu Hee Oh; Keun Il Kim; Dong-Er Zhang; Ok Sun Bang; Chin Ha Chung
Journal:  EMBO Rep       Date:  2009-03-06       Impact factor: 8.807

9.  Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model.

Authors:  C Ren; S Kumar; D Chanda; L Kallman; J Chen; J D Mountz; S Ponnazhagan
Journal:  Gene Ther       Date:  2008-07-03       Impact factor: 5.250

10.  Neural progenitor cell-mediated delivery of interferon beta improves neuroblastoma response to cyclophosphamide.

Authors:  Thomas L Sims; John B Hamner; Rebecca A Bush; Regan F Williams; Junfang Zhou; Seung U Kim; Karen S Aboody; Mary K Danks; Andrew M Davidoff
Journal:  Ann Surg Oncol       Date:  2008-08-23       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.